The immunocytokines market is estimated to be worth around USD 5.4 billion by 2030, claims Roots Analysis
30 juin 2021 10h55 HE
|
Roots Analysis
London, June 30, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of the “Immunocytokines Market, 2021-2030” report to its list of offerings. These engineered...
Study Identifies New Role of BioAegis’ ‘Inflammation Regulator’ Gelsolin Relevant for a Range of Inflammatory Diseases
08 avr. 2021 18h58 HE
|
BioAegis Therapeutics
Gelsolin mitigates vascular damage by preventing release of IL-1β microparticles after trauma of high pressure and decompression. Gelsolin is non-immunosuppressive unlike current treatments to quell...
Orion Biotechnology Receives Funding to Test OB-002 for Treatment of COVID-19
30 juil. 2020 10h51 HE
|
Orion Biotechnology Canada Ltd.
Ottawa, Canada, July 30, 2020 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today...
ORION BIOTECHNOLOGY SUCCESSFULLY COMPLETES PHASE I CLINICAL STUDY OF 0B-002H TOPICAL GEL FOR HIV PREVENTION
30 avr. 2020 13h21 HE
|
Orion Biotechnology Canada Ltd.
Ottawa, Canada, April 30, 2020 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today...
Gene Therapy Market is Likely to grow at the CAGR of 33.3% from 2017 to 2023
28 févr. 2019 08h01 HE
|
Allied Market Research
Portland, OR, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, Gene Therapy Market by Vector Type (Viral Vector and Non-viral Vector), Gene Type (Antigen,...
Hemispherx Biopharma Announces New Publication Enlarges the Understanding of Ampligen(R) Safety Profile Across Diverse Animal Species and Focuses on the Unique TLR-3 Receptor/Ampligen(R) Interaction
08 avr. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, April 8, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") announced today the peer-reviewed publication titled "Discordant Biological and...
Vista Partners Initiates Coverage on CytoSorbents Corporation (OTCQB: CTSO); $0.50 Price Target
29 janv. 2014 09h00 HE
|
Vista Partners LLC
SAN FRANCISCO, CA--(Marketwired - Jan 29, 2014) - Vista Partners announced today that it has initiated coverage on CytoSorbents Corporation (OTCQB: CTSO) ("The Company," or "CTSO"); with a twelve...